In 2023, the AHA formally defined cardiovascular-kidney-metabolic syndrome as a health disorder, citing the strong overlap between heart disease, kidney disease, type 2 diabetes, and obesity.
A version of this protocol may be able to induce tolerance in patients with end-stage heart and kidney failure who require combined heart and kidney transplantation,” the authors write.